The 34-gene classifier, ClearCode34, identifies prognostically distinct molecular subtypes of clear cell renal cell carcinoma (ccRCC) termed clear cell A (ccA) and clear cell B (ccB). The primary objective of this study was to describe clinical characteristics and comorbidities of relevance in patients stratified by ClearCode34.
In this retrospective analysis, 282 patients from Moffitt Cancer Center with ccRCC with gene expression analyses of the primary tumor were identified and ClearCode34 was applied to identify tumors as ccA or ccB. The medical record and institutional databases were queried to define patient characteristics, comorbidities, and outcomes.
We validated in this external cohort the superior overall survival, cancer-specific survival, and recurrence-free survival of ccA patients relative to ccB patients (P
ClearCode34, after considering distinct patterns of comorbidities in each molecular subtype, remains a strong prognostic tool in patients with ccRCC. Obesity and diabetes mellitus emerged as factors that may influence ccRCC phenotypes and further studies investigating the effect of these metabolic conditions functionally onto tumor biology are warranted. Additionally, use of angiotensin system inhibitors could be studied in the context of ccRCC molecular classification in future studies to better understand its effect on ccRCC outcomes.
Urologic oncology. 2015 Nov 03 [Epub ahead of print]
Scott M Haake, Samira A Brooks, Eric Welsh, William J Fulp, Dung-Tsa Chen, Jasreman Dhillon, Eric Haura, Wade Sexton, Philippe E Spiess, Julio Pow-Sang, W Kimryn Rathmell, Mayer Fishman
Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC. , Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. , Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA. , Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. , Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. , Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. , Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN. , Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.